Symposium - New York, United States
Diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) in the United States, and is associated with elevated cardiovascular morbidity and mortality. The progression of kidney disease in patients with diabetes occurs over many years, and interventions such as glycemic control and blood pressure lowering with inhibitors of the renin-angiotensin-aldosterone system have been shown to slow this progression. Despite the standard of care, the prevalence of patients with ESRD secondary to diabetic nephropathy continues to rise. Recently, several drugs in late clinical development have failed due to lack of efficacy and/or safety concerns. Finding and validating new targets to treat this condition has proven challenging due to lack of a deep understanding of the pathogenesis of diabetic nephropathy and biomarkers that can reliably define the rate of kidney function loss. This symposium reviews recent experimental approaches that may lead to the identification of targets for preventive or therapeutic interventions, and discusses the current challenges in the clinical development of therapeutic agents to treat diabetic kidney disease.
- Organization: New York Academy of Sciences
- Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges
Tue, Dec 09, 2014 - Tue, Dec 09, 2014 (08:00 - 17:00)
7 World Trade Cetner
250 Greenwich Street, 40th Floor, New York, United States
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
